Benign prostatic hyperplasia/urinary retention:

Indications for: FLOMAX

Benign prostatic hyperplasia (BPH).

Adult Dosage:

Swallow whole. Take ½ hr after same meal of each day. Initially 0.4mg once daily; may increase to 0.8mg once daily after 2–4 weeks if response is inadequate. If therapy is interrupted, resume at 0.4mg once daily and retitrate.

Children Dosage:

Not applicable.

FLOMAX Warnings/Precautions:

Rule out prostate cancer. Sulfa allergy. Syncope. End-stage renal disease. Severe hepatic impairment. Cataract or glaucoma surgery: do not initiate therapy (possible Intraoperative Floppy Iris Syndrome). Not for use in women.

FLOMAX Classification:

Alpha-1 blocker.

FLOMAX Interactions:

Do not use with other α-blockers or strong CYP3A4 inhibitors (eg, ketoconazole). Caution with concomitant moderate CYP3A4 inhibitors (eg, erythromycin), moderate or strong CYP2D6 inhibitors (eg, paroxetine, terbinafine), or CYP2D6 poor metabolizers (esp. with tamsulosin >0.4mg/day). Caution with concomitant cimetidine (esp. with tamsulosin >0.4mg/day) or warfarin. Symptomatic hypotension with concomitant PDE5 inhibitors.

Adverse Reactions:

Headache, abnormal ejaculation, dizziness, rhinitis, infection, asthenia, back pain, diarrhea, pharyngitis, chest pain, nausea, tooth disorder, blurred vision, cough, somnolence, sinusitis, libido decreased, insomnia; rare: priapism.


Hepatic. 94–99% serum protein bound.

Drug Elimination:

Renal (76%), fecal (21%). Half-life: 9–13 hours.

Generic Drug Availability:


How Supplied: